September 26, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares over potential securities laws violations by Pacira Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) concerning whether a series of statements by Pacira Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Pacira Pharmaceuticals Inc reported that its annual Total Revenue rose from $14.56 million in 2010 to $85.55 million in 2013. Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) grew from under $8 per share in early 2012 to as high as $109.94 per share in late August 2014.

Then on September 25, 2014-- Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced that it received a Warning Letter from the U.S. Food and Drug Administrations (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL (bupivacaine liposome injectable suspension).

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) declined from $106.29 per share on September 24, 2014, to $96.93 per share during September 25, 2014.